Search

Displaying results 3331 - 3340 of 10000 in total
  1. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  2. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    efficacy, especially in patients that respond poorly to anti-VEGF-A monotherapy. … [L40026] It received subsequent approval for the same indications in Canada in May 2022.

  3. Drug

    Toluene

    go.drugbank.com/drugs/DB11558
    InvestigationalVet approved

    Toluene is a colorless, liquid that is immiscible in water. It is a mono-substituted benzene derivative used in veterinary medicine as a treatment for various parasites in dogs and cats.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH. … It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.

    Synonyms: (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-, (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-
  5. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    Ziftomenib is a potent and highly selective menin inhibitor. … [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

  6. Drug

    Cyproterone acetate

    go.drugbank.com/drugs/DB04839
    ApprovedInvestigational

    It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. … An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties.

  7. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    Vusolimogene oderparepvec-wtpg is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy used, in combination with [nivolumab], to treat advanced melanoma. … on a PD-1-blocking antibody-based regimen.

  8. Drug

    Masoprocol

    go.drugbank.com/drugs/DB00179
    Investigational

    The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem] … A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Oxogluric acid

    go.drugbank.com/drugs/DB08845
    InvestigationalNutraceutical

    studies have shown a reduction in ammonia by oxogluric acid in hemodialysis patients. … In the United States a phase I clinical trial is investigating whether oxogluric acid precursors found in nutritional supplements can benefit patients with the metabolic disorder propionic acidemia.

  10. Drug

    Ginger

    go.drugbank.com/drugs/DB10344
    ApprovedInvestigational

    Ginger allergenic extract is used in allergenic testing.

    Mixtures: C Ottways Lax Tab